Sign in Subscribe
Drugs

Oncolytics Biotech Inc. Announces US Phase 2 Clinical Trial for REOLYSIN in Combination with Carboplatin and Paclitaxel in Lung Cancer Patients

Strategic Insights

— 1 min read

Oncolytics Biotech Inc. has announced the initiation of a US Phase 2 clinical trial utilizing intravenous administration of REOLYSIN in combination with carboplatin and paclitaxel in patients with squamous cell carcinoma of the lungs (SCC lung cancer). This clinical trial aims to assess the antitumor effect of the treatment regimen and evaluate its safety and tolerability in the study population. The trial will enroll up to 55 patients with metastatic stage IIIB, stage IV, or recurrent SCC lung cancer. The primary objective of the study is to assess the objective response rates in the study population.

Key Takeaways:

  • The clinical trial, REO 021, is a single-arm, open-label, Phase 2 study that will explore the use of REOLYSIN in combination with carboplatin and paclitaxel for the treatment of SCC lung cancer patients.
  • The trial will enroll up to 55 patients with metastatic stage IIIB, stage IV, or recurrent SCC lung cancer who are chemotherapy-naive for their metastatic or recurrent cancer.
  • The primary objective of the study is to assess the objective response rates in the study population, while secondary objectives include evaluating progression-free survival, overall survival, and the proportion of patients alive and free of disease progression at six months.
  • The study is part of a broader preclinical and clinical collaboration with the Cancer Therapy & Research Center at the University of Texas Health Science Center, which will involve up to five open-label, Phase 2 studies exploring the use of REOLYSIN in combination with chemotherapy for various cancer indications.
  • Principal Investigator Dr. Alain C. Mita expressed optimism about the study's potential to offer new hope to patients with lung cancer.

Statistics:

  • Up to 55 patients are expected to be treated in the trial.
  • The trial will explore the use of REOLYSIN in combination with carboplatin and paclitaxel in patients with SCC lung cancer.
  • The study population includes patients with metastatic stage IIIB, stage IV, or recurrent SCC lung cancer who are chemotherapy-naive.

Sources:

  • Oncolytics Biotech Inc. press release announcing the initiation of the US Phase 2 clinical trial.
  • Cancer Weekly editorial citing the Oncolytics Biotech Inc. press release.
  • NewsRx.com article referencing the Oncolytics Biotech Inc. press release.

Read more